Ensuring Safety Within the National Healthcare System

The government is moving forward with plans to formally introduce abortion medication. It has been seven years since the Constitutional Court declared the abortion ban unconstitutional in 2019.


Until now, abortion medications have not been officially approved in Korea, leading to unofficial distribution through online channels and other means. Once abortion medication is officially introduced, women will have, for the first time, the option to choose a medically supervised, clinically validated alternative to surgical abortion, under appropriate medical examination and prescription.

Won Minkyeong, Minister of Gender Equality and Family (left), and Oh Yukyung, Commissioner of the Ministry of Food and Drug Safety, are listening to Prime Minister Han Seongsuk's remarks regarding abortion medication at the National Policy Coordination Meeting held at the Government Seoul Office in Jongno-gu, Seoul on September 16, 2026. Photo by Jo Yongjun

Won Minkyeong, Minister of Gender Equality and Family (left), and Oh Yukyung, Commissioner of the Ministry of Food and Drug Safety, are listening to Prime Minister Han Seongsuk's remarks regarding abortion medication at the National Policy Coordination Meeting held at the Government Seoul Office in Jongno-gu, Seoul on September 16, 2026. Photo by Jo Yongjun

View original image

The Ministry of Gender Equality and Family, together with the Ministry of Health and Welfare and the Ministry of Food and Drug Safety, announced the "Plan for the Introduction of Medical Abortion Drugs" at the 14th National Policy Coordination Meeting held at the Government Complex Seoul on the morning of September 16. This follows President Lee Jaemyung’s directive on July 14, instructing officials to prepare for a Cabinet discussion on the possibility of permitting abortion medication.


The product currently under discussion for introduction is “Mifjimisojeong” by Hyundai Pharm. The package consists of one 200mg tablet of "Mifepristone," which ends pregnancy by blocking progesterone (a hormone necessary to maintain pregnancy), followed by four 200mcg tablets of "Misoprostol," which is used to induce uterine contractions and cervical dilation for labor induction and prevention/treatment of postpartum hemorrhage. If only Misoprostol is taken by itself up to 12 weeks of pregnancy, the success rate is 80-85%, but when both components are used together, the efficacy increases to 95%. Typically, Misoprostol is administered 1–2 days after taking Mifepristone.


Medication-based abortion is already widely used around the world. France became the first country to approve abortion medicine in 1988, followed by the United States in 2000, India in 2002, Australia in 2012, and Japan in 2023. As of 2024, approximately 100 countries now allow the use of medical abortion drugs. The World Health Organization (WHO) has also designated medical abortion drugs as essential medicines.


The decisive moment that accelerated this discussion was a recent authoritative interpretation by the Ministry of Government Legislation. On August 19, the ministry determined that even though medication is not explicitly listed as a method of artificial abortion under the Maternal and Child Health Act, product approval for abortion medication is still legally permissible. In the current situation, where the timeframe for legal abortion is not yet defined by law, if a drug meets the requirements for approval—such as safety and efficacy—the Ministry of Food and Drug Safety would be obligated to approve the product as indicated for artificial abortion. In short, the ministry cannot arbitrarily reject approval merely because legislation on abortion is not yet in place, opening a pathway for formal introduction if the drug meets regulatory requirements.


This interpretation arose because, although the abortion ban lost its effect, a legal and regulatory vacuum has persisted regarding abortion. The Constitutional Court issued a decision of unconstitutionality on the abortion ban in April 2019, but follow-up legislation specifying the timing and methods for legal abortion has not occurred, and abortion medications have likewise not been formally introduced in Korea.


The official introduction of abortion medication is significant for women’s health rights and self-determination. The Ministry of Gender Equality and Family stated, “Unregulated circulation and the widespread use of unverified alternatives are undermining safety, and women’s right to choose surgery or medication according to their health status is currently limited. The introduction of abortion medication is urgently needed to address rising costs and other socio-economic burdens.”

The Ministry of Food and Drug Safety has pledged to thoroughly review the safety, efficacy, and quality of abortion drugs, and to meticulously examine risk management plans and other documentation submitted for approval. The Ministry of Health and Welfare also stated that for the first two years after introduction, abortion drugs will be managed by requiring direct prescription and dispensing by physicians within medical institutions, with phased expansion to be considered after review of side effects and safety data.



Won Minkyoung, Minister of Gender Equality and Family, remarked, “Now that the government has formally announced plans to introduce abortion medication, procedures will become safer within the national healthcare system, and the burden on women who are compelled by socio-economic circumstances to seek abortion will be reduced.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing